Ciprofibrate

ApprovedSmall molecule

Sanofi

Ciprofibrate is one of 84 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

HypertriglyceridemiaActive, not recruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

HypertriglyceridemiaApproved

Active, not recruiting

Competition

Competitive Landscape

274 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Kerendia

Bayer

Phase 3

1 2

Spiriva

Boehringer Ingelheim

Phase 3

1 3

Inpefa

LLexicon Pharmaceuticals

Phase 3

1 4

Dalcetrapib

Roche

Phase 3

1 5

Maridebart Cafraglutide

Ciprofibrate

1 7

Repatha

Amgen

Preclinical

5 8

Mounjaro

Eli Lilly

Preclinical

1 9

Praluent

Regeneron

Preclinical

1 10

Calciferol

Alnylam Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Recruiting

Cardiovascular Disease

NCT06858332

Clinical

Trials by Indication[1]

Hypertriglyceridemia1 trial

Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia

Unknown status·HHospital Universitario Pedro Ernesto·Phase 4·NCT01480687·52 enrolled

Endothelial Function1 trial

Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions

Completed· Sanofi logo

Sanofi·Phase 4·NCT00350038·60 enrolled

Cardiovascular Disease1 trial

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Recruiting· Novartis logo

Novartis··NCT06858332·2,382 enrolled

PreDiabetes1 trial

Ciprofibrate and Pre-diabetes

Completed·MMaastricht University Medical Center·Phase 3·NCT03662984·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Ciprofibrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ciprofibrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ciprofibrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Ciprofibrate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hypertriglyceridemia1 trial

Endothelial Function1 trial

Cardiovascular Disease1 trial

PreDiabetes1 trial

References

Drug Info

Quick Facts

Related News